Ipsen media releases

Key highlights

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

– 27 April 2023 – 1 mins read

27 April 2023 – 1 mins read

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

Paris (France), 27 April 2023

Filter

Topics

Period

Filter by

Reset

Showing: 1 – 05 of 30 Press Releases

Show

Sort

Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.

– 26 May 2023

26 May 2023

Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.

PARIS, FRANCE, 26 May 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the re-examination of palovarotene as a potential treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva, by the Committee for Medicinal Product

Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases

– 17 May 2023

17 May 2023

Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases

PARIS, FRANCE, 17 May 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from its growing rare disease portfolio will be presented at the 55th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and

– 27 April 2023

27 April 2023

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

Paris (France), 27 April 2023

Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs

– 24 April 2023

24 April 2023

Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs

PARIS, FRANCE, 24 April 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Sandra Silvestri, M.D., Ph.D., as EVP, Chief Medical Officer and Head of Global Medical Affairs

Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP

– 16 March 2023

16 March 2023

Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP

PARIS, FRANCE, 16 March 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date, for the resubmitted New Drug Application (NDA) for investigational pa

1 2 3 4 … 6

Your dedicated contacts

Amy Wolf

Vice President, Corporate Brand Strategy and Communications

Ioana Piscociu

Senior Manager, Media Relations

Press Releases

Key highlights

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

Explore more press releases

Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.

Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs

Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP